The Hospital del Mar Medical Research Institute (IMIM), Hospital del Mar, the University of California-Davis and the University of Texas have launched a clinical trial to analyze how useful a food supplement can be for preventing the worst side effects of COVID-19. The study is looking at bovine-derived immunoglobulins, which have been shown in animal models to reduce the inflammation caused by infection, progression to more severe forms of the disease, and post-COVID syndrome. The first patients participating in the Randomized Open-Label Clinical Study Evaluating the Impact of EnteraGam, a Nutritional Intervention containing Bovine Plasma-Derived Immunoglobulin CoNcentrate, on Clinical Outcomes In People with COVID19 (PICNIC Study) are already taking two daily doses of this supplement.